Public Profile

Eris

Eris, officially known as Eris Lifesciences, is a prominent player in the Indian pharmaceutical industry, headquartered in India. Founded in 2007, the company has rapidly established itself as a leader in the development and marketing of high-quality generic medications, particularly in the therapeutic areas of diabetes, cardiovascular health, and respiratory diseases. With a strong operational presence across India and expanding international markets, Eris is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of formulations that are distinguished by their efficacy and affordability, catering to the needs of healthcare professionals and patients alike. Eris has achieved significant milestones, including a robust portfolio of over 100 products and a growing market share, positioning itself as a trusted name in the pharmaceutical sector.

DitchCarbon Score

How does Eris's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

16

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Eris's score of 16 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

Eris's reported carbon emissions

Eris currently does not have available carbon emissions data, as no specific figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This lack of information suggests that Eris may still be in the early stages of developing a comprehensive climate strategy or may not have publicly committed to specific emissions reduction goals. As the industry increasingly prioritises sustainability, it will be essential for Eris to establish clear climate commitments to align with global efforts in reducing carbon footprints.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Eris's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Eris is in IN, which has a very high grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Eris is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Natco Pharma

IN
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Tirupati Medicare Limited

IN
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Windlas Biotech Limited

IN
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Laurus Labs

IN
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Ajanta Pharma

IN
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Indoco Remedies

IN
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers